The News

Stay up to date with the latest news

Press Releases

TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer
April 8, 2025
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
November 13, 2024
TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases
June 26, 2024
TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration
January 3, 2024
TRexBio Announces Development Candidate, TRB-061, a Novel TNFR2 Agonist for the Treatment of Inflammatory Diseases
November 14, 2023
TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases
January 9, 2023
TRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases
March 8, 2022
TRexBio Announces Collaboration with Janssen to Discover Novel Targets for Immunology and Inflammation
January 6, 2022
TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases
June 22, 2021

In the News

TRexBio Raises $84M to Take In-house Immune Program into the Clinic
November 13, 2024 – Endpoints News
Lilly, J&J, Pfizer Pile in on Treg-Focused Biotech’s $84M Round
November 13, 2024 – FirstWord Pharma
TRex Bio Raises $84M to Compete in Crowded Immune Drug Field
November 13, 2024 – BioPharma Dive
TRexBio: restoring tissue immune homeostasis via Treg modulation
June 19, 2023 – BioCentury
Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio
January 9, 2023 – Endpoints News
Jurassic Ambitions: TRexBio Targets Tregs with Janssen Collaboration
January 10, 2022 – Genetic Engineering & Biotechnology News
T_reg engineers take aim at autoimmunity
November 9, 2021 – Nature Biotechnology
Biotech TRexBio has Jurassic day picking up ex-Lilly VP as CEO, snagging Big Pharma funding
Jun 22, 2021 – Fierce Biotch
TRexBio Chomps Down on $59 Million Series A for Immunobiology
Jun 22, 2021 – BioSpace
Big Pharma backers jump on board ‘Treg’ cartographer’s lead round with up to six candidates in the pipe
June 22, 2021 – Endpoints News